For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 9,840 | 7,317* | 8,461 | 6,991 |
| General and administrative | 6,444 | 4,372* | 4,746 | 4,186 |
| Total operating expenses | 16,284 | 11,689 | 13,207 | 11,177 |
| Loss from operations | -16,284 | -11,689* | -13,207 | -11,177 |
| Grant income | 22 | 22* | - | - |
| Interest income | 1,322 | 1,097* | 953 | 926 |
| Interest expense | 1,564 | 1,524* | 161 | 236 |
| Change in fair value of warrant liabilities | -7,643 | 1,989* | -1,146 | -5,691 |
| Total other income, net | 7,423 | -2,394* | 1,938 | 6,381 |
| Net income (loss) and comprehensive income (loss) | -8,861 | -14,084 | -11,269 | -4,796 |
| Basic EPS | -0.14 | -0.268 | -0.21 | -0.09 |
| Diluted EPS | -0.14 | -0.268 | -0.21 | -0.09 |
| Basic Average Shares | 62,361,897 | 52,491,656 | 54,894,347 | 51,489,929 |
| Diluted Average Shares | 62,361,897 | 52,491,656 | 54,894,347 | 51,489,929 |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)